# Endometriosis Imaging with $^{99m}$Tc-maraciclatide
# Presented at European Endometriosis Congress 2026

**London, UK, 27 April 2026.** Serac Healthcare Limited ("Serac Healthcare" or "the Company"), a clinical radiopharmaceutical company developing an innovative molecular imaging agent, announces that two oral presentations on the "Detecting Endometriosis expressed inTegrins using teChneTium-99m" imaging (DETECT) study, have been presented at the 8th European Endometriosis Congress which took place from 23rd to 25th April in Bologna, Italy.

Dr Tatjana Gibbons, an investigator on the study from the Nuffield Department of Women's and Reproductive Health at the University of Oxford, presented results from the study which aims to determine the feasibility of detecting endometriosis using $^{99m}$Tc-maraciclatide and single-photon emission computed tomography.

The presentation on **In vivo imaging of angiogenesis in endometriosis lesions** highlighted that in vivo characterisation of different lesion types was carried out for the first time in this study. The lesions were graded by their colour and their histology analysed and these findings were compared to the SPECT-CT images taken using maraciclatide. Based on the surgical data, highly angiogenic (red, red-mixed, or clear) lesions were 7.6 times more likely to be visualised on SPECT-CT than other lesion colours (yellow, brown, blue, black, white, or mixed). Immunohistochemical analysis of the excised lesions confirmed the presence of the angiogenic integrin αvβ3.

The presentation concluded that:
*"In vivo imaging of angiogenesis aligns with earlier in vitro findings, demonstrating that red endometriosis lesions exhibit greater angiogenic activity than other lesion types. These insights improve our understanding of lesion pathophysiology and may inform the development of targeted anti-angiogenic and anti-inflammatory therapies."*

The second presentation, **DETECTion of SPE and extra-pelvic endometriosis with a 20-minute $^{99m}$Tc-maraciclatide imaging scan** highlighted findings from the study specifically relating to the visualisation of superficial peritoneal endometriosis (SPE) and extra-pelvic endometriosis, which is poorly visualised by current non-invasive imaging modalities and for which definitive diagnosis still relies on direct visualisation at surgery. In this study, 99mTc-maraciclatide uptake was seen in all endometriosis subtypes including SPE and in all three cases of extra-pelvic endometriosis, identified by intraoperative thorascopic diagnosis.

The presentation concluded that:
*"This study demonstrates that 99mTc-maraciclatide SPECT-CT has potential as a non-invasive tool for detecting SPE and extra-pelvic endometriosis, particularly within the diaphragm and thorax. The scan also has the potential to visualise endometriotic lesions in other extra-pelvic sites. The ability to visualise endometriotic lesions in vivo may support early diagnosis, surgical planning, targeted therapy development, and deeper mechanistic insights into endometriosis."*

The abstracts are available in the EEC Abstract book published here: https://www.eec2026.com/abstract-book/

**-ENDS-**

**Maraciclatide is for investigational use only and is not approved by the FDA or UK and European regulatory authorities.**

**For more information, please contact:**


| | |
|---|---|
| Serac Healthcare Ltd | www.serachealthcare.com |
| David Hail, Chief Executive Officer | +44 (0)208 948 0000<br>info@seraclifesciences.com |
| Francetta Carr, Communications Director | +44 (0)7711 010820<br>francettacarr@seraclifesciences.com |


**Notes to Editors**

**About Serac Healthcare Ltd**
Serac Healthcare is a clinical radiopharmaceutical company with deep expertise in discovering, developing and commercialising innovative molecular imaging technologies. Using these targeted technologies to underpin personalised medicine in the fields of endometriosis and inflammatory arthritis, Serac Healthcare is focused on bringing to market effective tools to accelerate diagnosis, and to deliver earlier and more effective treatment decisions. Serac Healthcare Ltd is a wholly owned subsidiary of Serac Life Sciences Limited.

**About $^{99m}$Tc-maraciclatide**
$^{99m}$Tc-maraciclatide is a radio-labelled tracer which binds with high affinity to the cell adhesion protein $\alpha_v\beta_3$ integrin and images angiogenesis (new blood vessel formation) which is known to be critical to the establishment and growth of endometriotic lesions.

**About the DETECT study**
In the DETECT study, women with confirmed or suspected endometriosis who are due to undergo laparoscopy, a key-hole surgical procedure used to assess the organs in the abdomen and pelvis, are imaged with $^{99m}$Tc-maraciclatide before laparoscopic surgery. During surgery, tissue samples with identified endometriosis are collected and analysed to determine the presence of $\alpha_v\beta_3$. The laparoscopic and radiographic findings are compared to determine whether $^{99m}$Tc-maraciclatide holds potential as a novel, non-invasive method of detecting early-stage endometriosis.

The study is jointly sponsored by Oxford Endometriosis CaRe Centre and the Nuffield Department of Women's and Reproductive Health, Oxford University, and funded by Serac Healthcare Ltd who are providing the experimental imaging marker $^{99m}$Tc-maraciclatide. Further details are available on ClinicalTrials.gov here.

**About the European Endometriosis Congress**: www.eec2026.com